AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CLPT · NASDAQ · Medical - Devices

ClearPoint Neuro

Enables neurosurgery, laser therapy, CNS delivery, and neurocritical care with navigation tools.

$15.58

After-hours close+0.03 (+0.19%)

At close$15.55(−2.45%)

Something off on this page? Send us feedback.

Profile

ClearPoint Neuro, Inc.CLPTHealth Care

Sells stereotactic navigation systems, disposable devices, laser-therapy access, neurocritical-care fluid management, and CNS-delivery services for neurosurgeons and therapy developers, with recurring procedure use and partner trial progress shaping demand.

Offers neuro-only medical devices and development services for brain and spine procedures. The platform centers on ClearPoint navigation, SmartFrame hardware and software, SmartFlow cannulas, ClearPoint Prism laser therapy, and IRRAflow fluid-management systems added through the IRRAS acquisition.

Runs from Southern California, with activated centers and partner work spanning global clinical and research sites. Revenue comes from product sales, procedure-linked disposables, capital equipment, software, and service work that supports therapy programs from preclinical testing through clinical use.

Execution depends on device clearance and certification, hospital adoption of MRI-suite and operating-room workflows, therapy partners advancing CNS programs, and integration of the neurocritical-care line. Financing needs remain tied to operating losses, R&D, regulatory work, commercial expansion, and acquisition integration.

Company facts

CEOJoseph M. Burnett

ListedFeb 12, 2020

ExchangeNASDAQ

HeadquartersSolana Beach, CA

CountryUnited States

Employees172

CIK0001285550

ISINUS18507C1036

Key statistics

Market cap$466.3M

EPS (ttm)−$1.18

P/E (ttm)−13.18

ROE-188.1%

P/B43.09

P/S11.03

Dividend yield—

Beta1.82vs XLV 0.67

Year to date +10.8% · Average volume (30d) 599.0K

Analysts

Price target, next 12 months$23.50+51.1%Median of 3 analysts · vs the Aug 28 close

ConsensusBuy3 of 3 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $15.55

High$25.00+60.8%

Median$23.50+51.1%

Low$22.00+41.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior target	Target
Aug 4, 2026	Lake Street	Target	$30	$25
Aug 4, 2026	Stifel Nicolaus	Target	$16	$22
Jun 9, 2026	Stifel Nicolaus	Target	$9	$16

Earnings

EPS

Estimate−$0.31

ReportedDue Nov 5, 2026

Revenue

Estimate$12.3M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 3, 2026Q2 FY26	−$0.29	−$0.38	−32.6%	$12.7M	$10.9M	−14.6%	−16.25%
May 13, 2026Q1 FY26	−$0.28	−$0.32	−14.3%	$12.0M	$12.1M	+1.3%	+4.76%
Mar 17, 2026Q4 FY25	−$0.22	−$0.27	−22.7%	$10.1M	$10.4M	+3.5%	−13.89%
Nov 6, 2025Q3 FY25	−$0.20	−$0.21	−5.0%	$10.4M	$8.9M	−14.8%	−13.27%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$8.5M	$9.2M	$8.9M	$10.4M	$12.1M	$10.9M
Gross profit	$5.1M	$5.6M	$5.6M	$6.4M	$7.5M	$6.9M
Operating income	−$6.2M	−$5.7M	−$5.3M	−$7.0M	−$8.5M	−$10.2M
Net income	−$6.0M	−$5.8M	−$5.9M	−$7.8M	−$9.6M	−$11.3M
Diluted EPS	−$0.22	−$0.21	−$0.21	−$0.27	−$0.32	−$0.38
Gross margin	60.5%	60.3%	63.2%	61.5%	62.2%	63.6%
Operating margin	-72.6%	-61.6%	-59.5%	-67.7%	-69.9%	-94.2%

Fiscal years (4-quarter sums)FY21 $16.3M · FY22 $20.6M · FY23 $24.0M · FY24 $31.4M · FY25 $37.0M

Revenue by product · Q2 FY26

Biologics And Drug Delivery$4.0M · 53%

Capital Equipment And Software$1.3M · 17%

Biologics And Drug Delivery - Disposable Products$943.0K · 12%

Capital Equipment And Software - Systems And Software Products$881.0K · 12%

Capital Equipment And Software - Services$416.0K · 5%

Balance sheet, Jun 30, 2026Cash & short-term investments $29.4M · Total debt $63.9M · Total assets $86.7M · Shareholders' equity $10.8M

Dividends

No dividends on record.

Ownership

Institutions 46.73%14.01M sharesInsiders 3.84%1.15M sharesOther 49.43%14.82M shares

Shares outstanding 29.99M · Float 26.58M · 88.6% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	2.38M	7.94%	13F	Aug 7, 2026
Mak Capital One LLC	2.38M	7.92%	13F	Aug 14, 2026
Vanguard Capital Management LLC	1.23M	4.11%	13F	Aug 13, 2026
State Street Corp	816.5K	2.72%	13F	Aug 7, 2026
Geode Capital Management, LLC	749.9K	2.50%	13F	Aug 12, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jun 29, 2026	Joseph Burnett	director, officer: CEO and President	−20,000	$19.38
Jun 17, 2026	Joseph Burnett	director, officer: CEO and President	−61,843	$17.79
Jun 1, 2026	Timothy T. Richards	director	−5,415	$12.17
May 21, 2026	Matthew B. Klein	director	−16,000	$11.59
May 20, 2026	Lynnette C. Fallon	director	−5,091	$11.14